Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Zenagamtide

Stage Phase 3Stale

Sponsor Novo Nordisk A/S

Route oral and injection

Sources

registry, as of 2026-09-28Stale

https://clinicaltrials.gov/study/NCT07720271

Protocol section, NCT07720271 AMAZE 9, last update posted 2026-09-28

registry, as of 2026-10-06Stale

https://clinicaltrials.gov/study/NCT07861100

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 8500. Conditions Cardiovascular Risk; Obesity. This clinical study is being conducted to evaluate the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease (ASCVD) and excess body weight compared with placebo. The purpose of this clinical study is to find out if zenagamtide is safe and

ClinicalTrials.gov NCT07861100 protocol and results modules

registry, as of 2026-08-24Stale

https://clinicaltrials.gov/study/NCT07668401

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 400. Conditions Obesity; Overweight. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatme

ClinicalTrials.gov NCT07668401 protocol and results modules

registry, as of 2026-10-07Stale

https://clinicaltrials.gov/study/NCT07815067

A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 320. Conditions Overweight; Obesity. The purpose of this clinical study is to test how taking zenagamtide tablets with different meal/water variations affects how much zenagamtide enters the bloodstream in people who have overweight or obesity. All participants will get zenagamtide.

ClinicalTrials.gov NCT07815067 protocol and results modules

registry, as of 2026-10-16Stale

https://clinicaltrials.gov/study/NCT07868354

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 60. Conditions Overweight; Obesity; Type 2 Diabetes. The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get tirzepatide and zenagamtide.

ClinicalTrials.gov NCT07868354 protocol and results modules

registry, as of 2026-10-16Stale

https://clinicaltrials.gov/study/NCT07855133

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 60. Conditions Overweight; Obesity; Type 2 Diabetes. The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get semaglutide and zenagamtide.

ClinicalTrials.gov NCT07855133 protocol and results modules

Studies

AMAZE 9

Registry NCT07720271

Phase Phase 3

Status Recruiting

Enrollment 950

Start 2026-08-31

Primary completion 2028-06-27

Catalyst Primary completion. 2028-06-27Stale

zenagamtide

Placebo

AMBIENCE

Registry NCT07861100

Phase Phase 3

Status Not yet recruiting

Enrollment 8500

Start 2026-10-26

Primary completion 2030-09-16

Study completion 2030-09-16

Catalyst Primary completion. 2030-09-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Zenagamtide

Regimen once weekly

Comparator placebo

Population Cardiovascular Risk; Obesity

Placebo

Regimen once weekly

Population Cardiovascular Risk; Obesity

AMAZE 13

Registry NCT07668401

Phase Phase 3

Status Not yet recruiting

Enrollment 400

Start 2027-01-07

Primary completion 2029-01-11

Study completion 2029-01-11

Catalyst Primary completion. 2029-01-11. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Zenagamtide

Regimen once weekly

Comparator placebo

Population Obesity; Overweight

Placebo

Regimen once weekly

Population Obesity; Overweight

A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overwe

Registry NCT07815067

Phase Phase 1

Status Recruiting

Enrollment 320

Start 2026-09-07

Primary completion 2028-06-12

Study completion 2028-06-12

Catalyst Primary completion. 2028-06-12. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Zenagamtide subcutaneous (s.c.)

Regimen once weekly

Population Overweight; Obesity

Zenagamtide oral

Regimen once daily

Population Overweight; Obesity

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzep

Registry NCT07868354

Phase Phase 1

Status Recruiting

Enrollment 60

Start 2026-10-08

Primary completion 2028-09-07

Study completion 2028-09-07

Catalyst Primary completion. 2028-09-07. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Tirzepatide and Zenagamtide

Regimen once weekly

Population Overweight; Obesity; Type 2 Diabetes

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semagl

Registry NCT07855133

Phase Phase 1

Status Recruiting

Enrollment 60

Start 2026-10-05

Primary completion 2028-09-06

Study completion 2028-09-06

Catalyst Primary completion. 2028-09-06. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Semaglutide and Zenagamtide

Regimen once weekly

Population Overweight; Obesity; Type 2 Diabetes